Angelini Ventures, a global venture capital firm with a €300M commitment to invest in and create transformative healthcare companies, announced its investment in an online mental health platform, Serenis. Serenis is focused on facilitating access to digital tools and quality psychotherapy to make mental health care an accessible daily practice.
Mental health is a key investment area for Angelini Ventures. The investment group already funds innovative life sciences companies focused on finding novel therapies for patients suffering from mental illnesses. “The last few years have put a spotlight on mental health. Serenis provides a unique platform that matches patients in need with certified therapists. Our investment provides an opportunity to expand Angelini Ventures’ mental health focus with a digital health solution”, says Elia Stupka, Managing Director of Angelini Ventures, who joins the board of directors of Serenis as part of the investment.
Serenis, founded by Silvia Wang and Daniele Francescon, uses technology in support of the mental health therapeutic relationship between providers and patients, by leveraging data analytics to match providers with patients. Being digital allows the Serenis solution to not only break down barriers that prevent people from accessing psychotherapy, but also to improve the therapy itself, thanks to the impact of data analysis.
Angelini Ventures co-led a €2.7M extension of seed round funding in Serenis. The round included FG2 Capital, Lumen Ventures, Azimut Digitech Fund, Invictus Capital and various business angels. This investment brings Serenis' fundraising total to €6.5 million, less than a year after its inception. The funds raised will be used to support the growth of the company, launching new platform features, investing in awareness around the topic of mental health.
ABOUT ANGELINI VENTURES
Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investments firm focused on accelerating disruptive innovations and trends in digital health and life sciences. The group will invest €300M across a global portfolio led by investment professionals and advisors in Europe, North America and Asia.
Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies.